Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Asthma: Pathogenesis and Management

Asthma: Pathogenesis and Management

Asthma is a chronic pulmonary condition involving inflammation of the airways, hyper-reactivity, and reversible obstruction of the airways. This condition can significantly impact a person's quality of life, making breathing difficult and leading to distressing symptoms.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.

Antiasthma Drugs: Muscarinic Receptor Antagonists

Antiasthma Drugs: Muscarinic Receptor Antagonists

Muscarinic receptor antagonists, also known as antimuscarinic agents, are a class of bronchodilators used to treat asthma, although they are more commonly used to treat COPD. They work by inhibiting the action of acetylcholine (ACh), a neurotransmitter, on muscarinic receptors found in the airways.
Antimuscarinic agents compete with ACh for the same binding site on the muscarinic receptors. By binding to these receptors, they inhibit the downstream effects of ACh and block the parasympathetic...

Asthma-II: Pathophysiology and Classification

Asthma-II: Pathophysiology and Classification

Asthma is a prevalent chronic respiratory condition marked by inflammation and hyperresponsiveness of the airways. Its pathophysiology involves complex interactions among inflammatory pathways, immune responses, and neural mechanisms.
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:

Antiasthma Drugs: β2-Adrenoceptor Agonists

Antiasthma Drugs: β₂-Adrenoceptor Agonists

Bronchodilators are critical in managing asthma, a chronic respiratory condition characterized by airway constriction due to inflammation and hyper-reactivity. Specifically, bronchodilators ease this constriction by relaxing the bronchial muscles, facilitating easier breathing.
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce...

Asthma-IV: Diagnostic and Management

Asthma-IV: Diagnostic and Management

The diagnosis and management of asthma are comprehensive, encompassing clinical assessments, lung function tests, and pharmacological interventions. Here's an overview:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:

Asthma I: Introduction

Asthma I: Introduction

Asthma is a chronic inflammatory disorder of the airways characterized by variable airflow obstruction and heightened bronchial responsiveness to a wide range of triggers. The underlying inflammation leads to airway swelling, mucus hypersecretion, and smooth muscle constriction, all of which narrow the airway lumen and impede airflow. Clinically, asthma presents with recurrent episodes of wheezing, shortness of breath, chest tightness, and coughing, symptoms that typically vary in intensity and...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Inflammatory myofibroblastic tumour: a rare cause of central airway obstruction.

BMJ case reports·2018

Same author

Pulmonary tuberculosis.

Postgraduate medicine·2017

Same author

Response.

Chest·2014

Same author

A simple rule to identify patients with chronic obstructive pulmonary disease who may need treatment reevaluation.

Respiratory medicine·2014

Same author

Counterpoint: should fibrinolytics be routinely administered intrapleurally for management of a complicated parapneumonic effusion? No.

Chest·2014

Same author

Rebuttal from Drs Colice and Idell.

Chest·2014

Search research articles

Related Experiment Video

Updated: May 2, 2026

Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma

Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma

Published on: November 4, 2010

Tiotropium in asthma: a systematic review.

Elizabeth Befekadu¹, Claudia Onofrei¹, Gene L Colice²

¹MedStar Washington Hospital Center, Washington, DC, USA.

Journal of Asthma and Allergy

|March 7, 2014

Summary

This summary is machine-generated.

Tiotropium, a long-acting inhaled muscarinic antagonist, effectively improves lung function and maintains it when inhaled corticosteroids (ICS) are reduced in patients with moderate to severe persistent asthma. This add-on therapy shows no safety concerns.

Keywords:

LABA LAMA asthma inflammation inhaled corticosteroid lung tiotropium

More Related Videos

Dry Powder and Nebulized Aerosol Inhalation of Pharmaceuticals Delivered to Mice Using a Nose-only Exposure System

Dry Powder and Nebulized Aerosol Inhalation of Pharmaceuticals Delivered to Mice Using a Nose-only Exposure System

Published on: April 6, 2017

Methodology for Sputum Induction and Laboratory Processing

Methodology for Sputum Induction and Laboratory Processing

Published on: December 17, 2017

Related Experiment Videos

Last Updated: May 2, 2026

Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma

Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma

Published on: November 4, 2010

Dry Powder and Nebulized Aerosol Inhalation of Pharmaceuticals Delivered to Mice Using a Nose-only Exposure System

Dry Powder and Nebulized Aerosol Inhalation of Pharmaceuticals Delivered to Mice Using a Nose-only Exposure System

Published on: April 6, 2017

Methodology for Sputum Induction and Laboratory Processing

Methodology for Sputum Induction and Laboratory Processing

Published on: December 17, 2017

Area of Science:

Pulmonology
Pharmacology
Clinical Medicine

Background:

Asthma remains uncontrolled in many patients despite standard inhaled corticosteroid (ICS) therapy.
Investigating add-on therapies is crucial for improving asthma management in such cases.

Purpose of the Study:

To systematically review the efficacy and safety of tiotropium as an add-on therapy for asthma uncontrolled by ICS.
To evaluate tiotropium's role in patients also using long-acting inhaled beta2-agonists (LABA).

Main Methods:

Systematic review of randomized controlled trials (RCTs) identified through comprehensive database searches (MEDLINE, Cochrane, TRIP).
Included RCTs were at least 4 weeks in duration and reported on key asthma endpoints like lung function and exacerbation rates.
Data extraction focused on patient characteristics, study design, outcomes, and adverse events; meta-analysis was precluded by heterogeneity, necessitating descriptive summaries.

Main Results:

Five RCTs met inclusion criteria, evaluating tiotropium as add-on therapy to ICS or ICS/LABA in moderate to severe persistent asthma.
Tiotropium demonstrated efficacy in maintaining lung function during ICS tapering and improving lung function when added to ICS or ICS/LABA.
Compared to doubling ICS dose, tiotropium showed superior results; its benefits were similar to salmeterol when added to ICS/LABA.

Conclusions:

Tiotropium is a potentially beneficial add-on therapy for moderate to severe persistent asthma not adequately controlled by ICS or ICS/LABA.
The use of tiotropium as add-on therapy in this patient population does not present safety concerns.